Open in PodwiseOpen

Podcast cover

BiotechTV · News

BiotechTV - News

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

Episodes

Tour of Scotland: Tay Therapeutics is a product of University of Dundee's Drug Discovery Unit, and is working on small molecules - including a topical pan-BET that is in phase 2

Tour of Scotland: University of Dundee has established a world-class Centre for Protein Degradation, one of the hottest emerging modalities in biotech

Tour of Scotland: The Head of Business Development at University of Dundee's Drug Discovery Unit talks about how the university helps biopharma companies translate science into medicines

Tour of Scotland: Sir Michael Ferguson introduces the work in life sciences that has built up at The University of Dundee and the specialized centers that have come from it

A study published in JMIR today showed that Limbic's GenAI-powered chatbot elevated the standard of care for mental health patients in the UK’s National Health Service (NHS)

Analyst Thursdays: William Blair Senior Analyst Andy Hsieh talks about his new obesity sector report and the companies he initiated

On Rare Disease Day, Ultragenyx's Head of Gene Therapy Research explains the company's Rare Disease Bootcamp that helps families navigate drug development, and he also talks gene therapy science

Cambridge, UK based Amphista Therapeutics is developing a new generation of targeted protein degradation therapies that do not rely on cereblon or VHL

Cambridge, UK based Ignota Labs raised a $6.9M seed funding today and will use AI to understand why otherwise promising therapies have failed on tox by surprise and then to reengineer them

With unique license agreements in place with local universities and an additional $260M recently raised, Cambridge, UK based Apollo Therapeutics is building out a substantial pipeline

From Boston: Stifel Senior Analyst Paul Matteis talks about the orexin class of wakefulness medicines in development, and comments on recent news from companies he covers

Australia based Aravax, which is using a peptide based approach to food allergy treatments with the goal of avoiding inflammation, is building out late stage manufacturing capabilities in Oxford, UK

Oxford based Theolytics is leveraging a library of 100M variants of adenoviruses for a bottom up approach to oncolytic virus cancer drug development

With three approved products and filings for more over the near term, Axsome's CEO describes the scale and reach this company is building in the CNS space

Stoke Therapeutics' CEO Ed Kaye discusses today's partnership news with Biogen on Zorevunersen for the treatment of Dravet syndrome

The CEO of Solid Biosciences discusses today's data release of the company's microdystrophin gene therapy candidate for Duchenne muscular dystrophy

Paula Brown Stafford, CEO of the global CRO Allucent, discusses how the company is purpose built to partner with mid-to-small sized biopharma companies on their success

Welcoming Ryan Flinn as BiotechTV's new 'AI in Biotech' contributor

Oppenheimer's Head of Healthcare Investment Banking shares his take on 2025 and highlights M&A, IPOs, and the ability of companies to raise money this year

John Maraganore shares his take on biotech in 2025 and discusses the science behind his recently launched RNAi company, City Therapeutics

Page 24

Follow this podcast in Podwise

Sign in to get AI summaries, transcripts and mind maps for any episode, including new ones.

Open in Podwise